利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.067 秒)

    Modified MELK peptides and vaccines containing the same
    76.
    发明授权
    Modified MELK peptides and vaccines containing the same 有权
    改良的MELK肽和含有它们的疫苗

    公开(公告)号：US08871719B2

    公开(公告)日：2014-10-28

    申请号：US13574774

    申请日：2011-01-24

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K38/00 ,  A61K39/00 ,  C12N9/12 ,  A61K39/39

    CPC分类号： C12Y207/11025 ,  A61K39/0011 ,  A61K39/39 ,  C12N9/1205

    摘要： Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.

    摘要翻译： 由修饰的MELK表位肽或其免疫活性片段的氨基酸序列组成的分离肽，其结合HLA抗原并且具有比野生型MELK表位肽更高的细胞毒性T淋巴细胞（CTL）诱导性，因此适用于 本文描述了癌症免疫治疗或子宫内膜异位症免疫治疗的背景，更特别的是癌症或子宫内膜异位症疫苗。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 进一步提供了编码这些上述肽中的任何一种的核酸以及包含上述肽或核酸中任何一种的药物物质和组合物。 本发明的肽，核酸，药物和组合物在癌症，肿瘤和子宫内膜异位症的治疗中具有特别的用途。

    Genes and polypeptides relating to breast cancers
    77.
    发明授权
    Genes and polypeptides relating to breast cancers 有权
    与乳腺癌相关的基因和多肽

    公开(公告)号：US08673548B2

    公开(公告)日：2014-03-18

    申请号：US12377024

    申请日：2007-08-10

    申请人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Toyomasa Katagiri ,  Shuichi Nakatsuru

    IPC分类号： C12Q1/00 ,  C07K14/00

    CPC分类号： C07K16/18 ,  A61K31/7088 ,  C07K14/47 ,  C07K14/4748 ,  C12N2310/14 ,  C12Q1/485 ,  G01N33/5011 ,  G01N33/5035 ,  G01N33/57415 ,  G01N2333/9121 ,  G01N2510/00

    摘要： The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.

    摘要翻译： 本申请提供了新的人类基因A7322，其表达在乳腺癌中显着升高。 本申请还提供了人类基因F3374，其在乳腺癌中的表达显着升高。 由此编码的这些基因和多肽可用于例如乳腺癌的诊断，以及用于开发针对乳腺癌的药物的靶分子。 本发明的特征在于筛选PBK / TOPK的激酶活性的调节剂的方法。 本发明还提供筛选用于预防或治疗癌症（例如乳腺癌）的药剂的方法。

    WDHD1 PEPTIDES AND VACCINES INCLUDING THE SAME
    78.
    发明申请
    WDHD1 PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    WDHD1肽和疫苗包括它们

    公开(公告)号：US20130309259A1

    公开(公告)日：2013-11-21

    申请号：US13880442

    申请日：2011-10-20

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： C07K7/06

    CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/47

    摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。

    C18ORF54 PEPTIDES AND VACCINES INCLUDING THE SAME
    79.
    发明申请
    C18ORF54 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
    C18ORF54肽和疫苗，包括它们

    公开(公告)号：US20130287805A1

    公开(公告)日：2013-10-31

    申请号：US13880632

    申请日：2011-10-19

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K39/00

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  C07K14/47

    摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 35, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequences of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：35的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。